Riskpilot← Back to searchSign inGet full accessCUTISAN LABORATORIUM ApS
APSActiveCVR 76570612Haraldstedvej 99Manufacture of perfumes and toilet preparations · NACE 2042Est. 19841 employees
Revenue 2024
DKK -17K
+3% vs 2023
EBITDA margin
1016.5%
+47% vs 2023
Equity ratio
39.6%
Financial strength
Net profit 2024
DKK -37K
+88% vs 2023
| Revenue | DKK -17K | +3% |
| EBITDA | DKK -170K | +47% |
| Net profit | DKK -37K | +88% |
| Total assets | DKK 1,3M | -5% |
| Equity | DKK 520K | -7% |
| Employees | 1 | — |
Legal name
CUTISAN LABORATORIUM ApS
CVR number
76570612
Legal form
Anpartsselskab
NACE code
2042 · Manufacture of perfumes and toilet preparations
Founded
22. juni 1984
Share capital
DKK 500.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør alene eller af bestyrelsens formand i forening med et andet medlem af bestyrelsen.
Company purpose
Selskabets formål er at drive handels- og fabrikationsvirksomhed
Address
Haraldstedvej 99
Phone
+4561676479
Email
cutisan@dyrbakholst-christensen.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.858 | 4.016 | 4.822 | 4.115 | 4.332 | 3.311 | 3.292 | 2.070 | -219 | -156 | -16 | -16 | -17 |
| Staff expenses | -2.356 | -2.369 | -2.416 | -2.420 | -1.953 | -1.559 | -1.511 | -1.840 | -394 | -242 | -102 | -306 | -153 |
| EBITDA | 1.501 | 1.647 | 2.406 | 1.695 | 2.380 | 1.753 | 1.781 | 216 | -612 | -406 | -118 | -322 | -170 |
| Depreciation & amort. | 97 | 82 | 96 | 101 | -105 | -117 | -86 | -78 | -22 | -14 | -1 | -0 | -0 |
| EBIT | 1.404 | 1.565 | 2.310 | 1.594 | 2.274 | 1.636 | 1.694 | 137 | -634 | -421 | -120 | -322 | -170 |
| Net financials | 5 | 9 | 9 | -6 | -5 | -13 | -23 | -27 | -11 | -2 | -1 | 0 | 1 |
| Profit before tax | 1.409 | 1.574 | 2.319 | 1.588 | 2.270 | 1.623 | 1.671 | 110 | -645 | -422 | -121 | -322 | -169 |
| Tax | 353 | 393 | 569 | 374 | 501 | 357 | 368 | 24 | 51 | -0 | -0 | -0 | -131 |
| Net profit | 1.056 | 1.181 | 1.750 | 1.214 | 1.769 | 1.265 | 1.304 | 86 | -696 | -422 | -121 | -322 | -37 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6.002 | 6.888 | 7.921 | 6.793 | 7.470 | 6.831 | 8.273 | 4.998 | 1.860 | 1.127 | 890 | 1.378 | 1.313 |
| Equity | 5.299 | 5.730 | 6.281 | 5.494 | 6.063 | 5.728 | 5.032 | 4.118 | 1.422 | 999 | 879 | 557 | 520 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 703 | 1.158 | 1.640 | 1.299 | 1.407 | 1.103 | 3.241 | 880 | 438 | 127 | 11 | 820 | 794 |
| Total debt | 703 | 1.158 | 1.640 | 1.299 | 1.407 | 1.103 | 3.241 | 880 | 438 | 127 | 11 | 820 | 794 |
EBITDA margin
-16993400.0%
This company
15.8%
Market median
-107553265% vs market
20122024
Equity ratio
39.6%
This company
38.2%
Market median
+4% vs market
20122024
Return on equity
-7.2%
This company
18.4%
Market median
-139% vs market
20122024
Net profit margin
-3736200.0%
This company
8.1%
Market median
-46126026% vs market
20122024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20122024
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Audit | 1996 | — | — | |
DH Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
JA Audit | Audit | 1984 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1984 | — | — | |
| Chairman | 1984 | — | — | |
| Board of Directors | 1984 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
SIMPRINCO ApS | Company | 100.0% | 100.0% | 2016 |
SUBIA AF 1998 ApS | Company | 20.0% | 20.0% | 2003 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SIMPRINCO ApS
CUTISAN LABORATORIUM ApS Board members of CUTISAN LABORATORIUM ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| REVISIONSFIRMAET MUNCH-NIELSEN I/S | Audit | 0 companies |
| Dan Holst-Christensen | Chief Executive Officer | 0 companies |
| Jens Anker Aundrup | Audit | 0 companies |
| Bo Holst-Christensen | Board of Directors | 0 companies |
| Tonny Holst-Christensen | Chairman | 0 companies |
| Githa Daugaard Holst-Christensen | Board of Directors | 0 companies |
| Bjørn Ove Holst-Christensen | Chairman | 0 companies |